2023 Was a tough year with the biopharma sector, with quite a few businesses downsizing and restructuring their workforces to remain afloat. You'll find signs of recovery, as mergers and acquisitions picked up over the pharmaceutical and life sciences marketplace during the latter part of 2023 and have continued their https://sites.google.com/view/bio-sites/blog